198 related articles for article (PubMed ID: 16611189)
21. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.
Fireman M; Indest DW; Blackwell A; Whitehead AJ; Hauser P
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S286-91. PubMed ID: 15768336
[TBL] [Abstract][Full Text] [Related]
22. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
Freedman K; Nathanson J
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
24. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection.
Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Bartolomé J; Pardo M; Carreño V
J Med Virol; 2007 Mar; 79(3):236-41. PubMed ID: 17245725
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006.
Cacoub P; Halfon P; Rosenthal E; Pialoux G; Benhamou Y; Perronne C; Pol S;
J Hepatol; 2008 Jan; 48(1):35-42. PubMed ID: 17945375
[TBL] [Abstract][Full Text] [Related]
26. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
27. HCV virological assessment.
Forns X; Costa J
J Hepatol; 2006; 44(1 Suppl):S35-9. PubMed ID: 16343682
[TBL] [Abstract][Full Text] [Related]
28. Late liver-related mortality from complications of transfusion-acquired hepatitis C.
Kamitsukasa H; Harada H; Tanaka H; Yagura M; Tokita H; Ohbayashi A
Hepatology; 2005 Apr; 41(4):819-25. PubMed ID: 15793849
[TBL] [Abstract][Full Text] [Related]
29. Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C virus.
Hunt J; Hagan J; Nobles J; Wold C; Fazekas-May M; Gilbert J; Friedlander PL
Laryngoscope; 2005 Oct; 115(10):1882-6. PubMed ID: 16222215
[TBL] [Abstract][Full Text] [Related]
30. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection.
Fultz SL; Justice AC; Butt AA; Rabeneck L; Weissman S; Rodriguez-Barradas M;
Clin Infect Dis; 2003 Apr; 36(8):1039-46. PubMed ID: 12684917
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C.
Mailliard ME; Capadano ME; Hrnicek MJ; Gilroy RK; Gulizia JM
Hepatology; 2009 Aug; 50(2):361-8. PubMed ID: 19585621
[TBL] [Abstract][Full Text] [Related]
32. Understudied populations with hepatitis C.
Strader DB
Hepatology; 2002 Nov; 36(5 Suppl 1):S226-36. PubMed ID: 12407598
[TBL] [Abstract][Full Text] [Related]
33. Which patients with hepatitis C virus should be treated?
Shamoun DK; Anania FA
Semin Gastrointest Dis; 2000 Apr; 11(2):84-95. PubMed ID: 10803633
[TBL] [Abstract][Full Text] [Related]
34. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.
Hauser P
Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S35-50. PubMed ID: 15081102
[TBL] [Abstract][Full Text] [Related]
35. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
Bader T
J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
[No Abstract] [Full Text] [Related]
36. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people.
Giannini EG; Romagnoli P; Testa R
Am J Gastroenterol; 2006 Feb; 101(2):406-7. PubMed ID: 16454854
[No Abstract] [Full Text] [Related]
37. Sustained virological response following extremely short antiviral treatment in selected HCV carriers with persistently normal ALT.
Puoti C; Guarisco R; Spilabotti L; Bellis L
Dig Liver Dis; 2010 Oct; 42(10):745. PubMed ID: 20303840
[No Abstract] [Full Text] [Related]
38. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.
Jafferbhoy H; Miller MH; Dunbar JK; Tait J; McLeod S; Dillon JF
J Viral Hepat; 2012 Feb; 19(2):112-9. PubMed ID: 22239500
[TBL] [Abstract][Full Text] [Related]
39. A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use.
Sockalingam S; Blank D; Banga CA; Mason K; Dodd Z; Powis J
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1377-84. PubMed ID: 23680911
[TBL] [Abstract][Full Text] [Related]
40. Reasons for non-treatment of hepatitis C in veterans in care.
Butt AA; Wagener M; Shakil AO; Ahmad J
J Viral Hepat; 2005 Jan; 12(1):81-5. PubMed ID: 15655052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
